LOX and breast carcinoma: Liu JL et al. conducted immunohistochemistry analyses on 111 paired breast cancer and adjacent tissues, as well as 20 benign breast tumour tissues; their findings revealed a significantly greater expression of LOX in breast cancer tissues, with a rate of 48.6% (54/111), compared to adjacent tissues (26.1%; 29/111), and benign lesions (20.0%; 4/20).